James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Tesla Motors Inc: TSLA Aims to Ease Charging on the Road With Sheetz Talks

Tesla stock may still be facing plenty of headwinds, but in this particular instance, being a pioneer is compelling to TSLA investors.

Alcoa Inc: AA Stock Is Still a Huge Liability

Alcoa stock is up today following the release of more details on the upcoming split, but on a net basis, there's not actually any upside.

Why Barrick Gold Corporation (USA) (ABX), Dow Chemical Co (DOW) and The Kroger Co (KR) Are 3 of Today’s Worst Stocks

Barrick Gold (ABX), Dow Chemical (DOW) and Kroger (KR) were among the few losers on an otherwise (very) bullish day.

Twitter Inc: TWTR Stock Just Got a Lot More Buy-Worthy … For Some

TWTR stock was tough to own in 2015, but the company as well as shares have been quietly turning things around in 2016.

GW Pharmaceuticals PLC- ADR (GWPH): A Beacon of Light in an Otherwise Grim Market

GW Pharmaceuticals (GWPH) just sent a bullish message to the market today, turning some lemons into lemonade.